<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35344477</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>30</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>01</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1607-8454</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>27</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Hematology (Amsterdam, Netherlands)</Title>
          <ISOAbbreviation>Hematology</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Serum immunoglobulin G as a discriminator of infection in follicular lymphoma patients undergoing chemotherapy with bendamustine in combination with rituximab.</ArticleTitle>
        <Pagination>
          <StartPage>384</StartPage>
          <EndPage>395</EndPage>
          <MedlinePgn>384-395</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/16078454.2022.2051863</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">Chemotherapy, including bendamustine, usually causes lymphocytopaenia and hypogammaglobulinaemia as side effects in patients with haematological malignancies. Therefore, the possibility has been considered that these immunological adverse events induced by bendamustine may lead to infectious diseases. However, lymphocytopaenia and/or hypogammaglobulinaemia have not yet been shown to have a statistically significant association with infection in cancer patients who receive bendamustine.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We retrospectively studied 27 patients with relapsed or refractory indolent follicular lymphoma who were treated with bendamustine and rituximab (BR). In order to elucidate relationships between immune-related laboratory parameters (i.e. peripheral blood leukocyte, neutrophil, lymphocyte and immunoglobulin G [IgG]) and infectious events, receiver operating characteristic (ROC) curve and multivariate logistic regression analyses were performed.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Infectious diseases occurred in 11 patients (11/27, 41%), including 3 (3/27, 11%) with severe diseases. The area under the ROC curve (AUC) showed that the lowest IgG level during and after BR discriminated infectious events (cut-off value, 603 mg/dL) with 81.8% sensitivity and 68.8% specificity (AUC, 0.76; 95% CI, 0.52-0.90). Furthermore, a multivariate regression analysis revealed that the minimal serum IgG value during and after BR therapy was the only variable that was significantly associated with infection (odds ratio, 8.29; 95% CI, 1.19-57.62; <i>p</i> value, 0.03).</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Serum IgG ≤603 mg/dL during and after BR therapy was independently associated with an increased risk of infection. The monitoring of serum IgG during chemotherapy may help to predict the development of infection in blood cancer patients undergoing chemotherapy with bendamustine in combination with rituximab.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Hirata</LastName>
            <ForeName>Akie</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Laboratory Medicine, NHO Kyushu Cancer Center, Fukuoka, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Medical Information Center, Kyushu University Hospital, Fukuoka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Miyashita</LastName>
            <ForeName>Kaname</ForeName>
            <Initials>K</Initials>
            <Identifier Source="ORCID">0000-0002-7461-8829</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Hematology, NHO Kyushu Cancer Center, Fukuoka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tanaka</LastName>
            <ForeName>Takafumi</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hematology, NHO Kyushu Cancer Center, Fukuoka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hirata</LastName>
            <ForeName>Kiyoko</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cell Therapy, NHO Kyushu Cancer Center, Fukuoka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Narazaki</LastName>
            <ForeName>Taisuke</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hematology, NHO Kyushu Cancer Center, Fukuoka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Utsunomiya</LastName>
            <ForeName>Hayato</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cell Therapy, NHO Kyushu Cancer Center, Fukuoka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ohno</LastName>
            <ForeName>Hirofumi</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cell Therapy, NHO Kyushu Cancer Center, Fukuoka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nakashima</LastName>
            <ForeName>Eriko</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hematology, NHO Kyushu Cancer Center, Fukuoka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tachikawa</LastName>
            <ForeName>Yoshimichi</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hematology, NHO Kyushu Cancer Center, Fukuoka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Choi</LastName>
            <ForeName>Ilseung</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hematology, NHO Kyushu Cancer Center, Fukuoka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Taguchi</LastName>
            <ForeName>Kenichi</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Laboratory Medicine, NHO Kyushu Cancer Center, Fukuoka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Suehiro</LastName>
            <ForeName>Youko</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hematology, NHO Kyushu Cancer Center, Fukuoka, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Cell Therapy, NHO Kyushu Cancer Center, Fukuoka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Hematology</MedlineTA>
        <NlmUniqueID>9708388</NlmUniqueID>
        <ISSNLinking>1024-5332</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009588">Nitrogen Mustard Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>4F4X42SYQ6</RegistryNumber>
          <NameOfSubstance UI="D000069283">Rituximab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>981Y8SX18M</RegistryNumber>
          <NameOfSubstance UI="D000069461">Bendamustine Hydrochloride</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069461" MajorTopicYN="N">Bendamustine Hydrochloride</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008224" MajorTopicYN="Y">Lymphoma, Follicular</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009588" MajorTopicYN="Y">Nitrogen Mustard Compounds</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069283" MajorTopicYN="N">Rituximab</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Lymphoma</Keyword>
        <Keyword MajorTopicYN="N">bendamustine</Keyword>
        <Keyword MajorTopicYN="N">hypogammaglobulinaemia</Keyword>
        <Keyword MajorTopicYN="N">immunoglobulin G (IgG)</Keyword>
        <Keyword MajorTopicYN="N">infection</Keyword>
        <Keyword MajorTopicYN="N">secondary immunodeficiency</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>28</Day>
          <Hour>17</Hour>
          <Minute>9</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35344477</ArticleId>
        <ArticleId IdType="doi">10.1080/16078454.2022.2051863</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
